Drug Profile
Campylobacter jejuni vaccine - Emergent BioDefense Operations Lansing
Alternative Names: CAMPYVAXLatest Information Update: 02 Sep 2015
Price :
$50
*
At a glance
- Originator Emergent BioDefense Operations Lansing
- Developer Emergent BioDefense Operations Lansing; United States Army Medical Research Institute of Infectious Diseases
- Class Bacterial vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Campylobacter infections
Most Recent Events
- 16 Jun 2003 The assets of Antex Biologics and Antex Pharma have been acquired by BioPort Corporation
- 05 Nov 2001 A phase II trial conducted in collaboration with the US Department of Defense has been completed
- 19 Oct 2001 Antex Biologics has completed phase I trials funded by the US Army SBIR and the US Army has invited Antex to submit an application for phase II trials